<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0310234286
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1984
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DESFERAL VIAL 500MG
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DEFEROXAMINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        110.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS PHARMA AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS PHARMA AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        V03AC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharmacotherapeutic group:<br />Desferal contains the active substance desferrioxamine, which is a so-called &ldquo;chelator&rdquo;.It is used to<br />remove excess iron or aluminium from the body.<br />Therapeutic indications:<br />Repeated blood transfusions may be necessary in patients suffering from certain types of anemia such as<br />thalassemia. However, repeated blood transfusions can cause a build-up of excess iron. This is because<br />blood contains iron and the body does not have a natural way to remove the excess iron that comes with<br />blood transfusions. Over time, the excess iron can damage important organs such as the liver and heart.<br />Desferal removes this excess iron and can therefore be used to treat chronic iron overload. Desferal can be<br />used to treat adults, adolescents and children.<br />It can also be used to:<br /> treat acute iron poisoning,<br /> treat chronic aluminum overload in patients with severe kidney disease who require regular dialysis.<br />Under certain circumstances, dialysis can lead to an excess build-up of aluminum.<br /> Test for iron or aluminum overload.<br />How Desferal works:<br />Desferal traps and removes excess iron or aluminum, which is then excreted through the urine and faeces.<br />Monitoring during treatment with Desferal:<br />You may have to take certain blood and urine tests before and during treatment.<br />For patients with iron overload, levels of iron (ferritin) in your body will be monitored to see how well<br />Desferal is working. Your sight and hearing will also have to be tested. In children, growth and body<br />weight will be checked at regular intervals. Your doctor will take these tests into consideration when<br />deciding on the dose of Desferal most suitable for you.<br />Your doctor will also evaluate your heart function if you take vitamin C while using Desferal.<br />If you have any questions about how Desferal works or why this medicine has been prescribed for you,<br />ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow all the doctor&rsquo;s instructions carefully. They may differ from the general information contained in<br />this leaflet.<br />a. Do not use Desferal<br /> If you are allergic (hypertensive) to Desferal or any of the other ingredients of Desferal listed at the<br />end of this leaflet (except where successful desensitization makes Desferal treatment possible).<br />If this applies to you, tell your doctor and do not use Desferal.<br />If you think you may be allergic to Desferal, ask your doctor for advice.<br />b. Take special care with Desferal<br />Before using Desferal, tell your doctor if you have:<br /> Any kidney disorders.<br />Tell your doctor right away, if you experience any of the following symptoms during treatment with<br />Desferal:<br /> High fever, sore throat, shortness of breath, abdominal pain, acute diarrhea or general discomfort<br />(signs of fungal or bacterial infections)<br /> Severely decreased urine output (sign of kidney disorders)<br /> Visual and hearing disorders.<br /> Dizziness, light-headedness (signs of low blood pressure), breathlessness that can occur if the drug is<br />given too rapidly when Desferal is administered by infusion into a vein. See also below section 3 &ldquo;If<br />you use more Desferal than you should&rdquo;.<br /> Heart disorders, a possible symptom in patients who use Desferal and also take high doses of Vitamin<br />C. If your doctor prescribes vitamin C supplements, make sure you have been using Desferal<br />regularly for at least 1 month before you start taking vitamin C. Also, take vitamin C only in the doses<br />recommended by your doctor. Do not exceed the daily dose of 200 mg.<br />Tell your doctor if you notice that:<br /> Your child treated with Desferal has slower than normal growth.<br />Please note that your urine may turn reddish-brown during treatment with Desferal. This is because there<br />is more iron in your urine. This is usually nothing to worry about, but if you are worried, talk to your<br />doctor or nurse.<br />c. Taking other medicines<br />Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, in addition to<br />Desferal, including medicines obtained without a prescription. This includes in particular:<br /> medicines containing prochlorperazine, a neuroleptic drug used to treat neurological disorders,<br /> vitamin C (doses above 200 mg daily during treatment with Desferal). Do not take more than 200 mg<br />of vitamin C per day (see above section Take special care),</p><p>gallium-67, a medicine given before imaging (scanning), which is used in diagnosis of certain<br />diseases.<br />You may need to change the dosage of the other medicine, or stop taking it altogether.<br />Please tell your &lt;doctor, health care provider or pharmacist if you are taking or have recently taken any<br />other medicines, including medicines obtained without a prescription.<br />d. Older People<br />Desferal can be used by elderly patients at the same doses as for other adults.<br />e. Children and adolescents<br />Desferal can be used in children and adolescents.<br />f. Pregnancy and breast-feeding<br />You should tell your doctor if you are pregnant, are planning to become pregnant, or are breastfeeding.<br />In general, you should not use Desferal during pregnancy and breast-feeding unless your<br />doctor advises you to do so. Your doctor will discuss with you the potential risk of using<br />Desferal during pregnancy.<br />Breast-feeding is not recommended during treatment with Desferal. Tell your doctor if you are<br />breast-feeding.<br />Ask your doctor, health care provider or pharmacist for advice before taking any medicine.<br />g. Driving and using machines<br />Desferal may affect your sight or hearing, make you feel dizzy, or cause other disturbances of<br />nervous function. If you experience such effects, do not drive or operate any tools or machines<br />until you feel well again.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow your doctor&rsquo;s instructions carefully. Do not exceed the recommended dose.<br />Your doctor will calculate the dose you need and tell you how much Desferal to use. Depending on how<br />you respond to treatment, your doctor may suggest a higher or lower dose. Desferal is intended for use as a solution in water for injection(s). Dissolve Desferal powder in the &ldquo;water for injection&rdquo; that your<br />pharmacist has given you. At the recommended concentration of 95mg/mL (for subcutaneous injection),<br />the solution appears colorless to slightly yellowish. The solution should be clear. Do not use opaque or<br />cloudy solutions.</p><p>&nbsp;</p><p>Treatment for chronic iron overload<br />Your doctor will adjust the dose to your particular condition. In most patients, the daily dose is 20 to 60<br />mg per kilogram body weight.<br />Desferal can be given by slow infusion, under the skin (subcutaneous injection using an infusion pump),<br />by infusion into a vein, or by injection into a muscle.<br />Your doctor or nurse may prepare your injection for you, or you may be taught how to do so yourself. For<br />long-term treatment of iron overload, it is particularly convenient to give Desferal slowly under the skin<br />for 8 to 12 hours (e.g. overnight), using a portable light-weight infusion pump. Desferal is usually used<br />with a pump 5 to 7 times a week. The pump should be set up carefully under very clean conditions.<br />Follow the instructions below for preparing the solution and infusing it under the skin:<br />1. Draw the water for injection into a syringe.<br />2. After cleaning the rubber stopper of the Desferal vial with alcohol, inject the content of the syringe<br />into the vial.<br />3. Shake the vial thoroughly to dissolve the powder.<br />4. Draw the solution so obtained into the syringe.<br />5. Attach the extension tube to the syringe, connect the extension tube to the butterfly-type needle, and<br />then fill the empty space in the tube with the solution in the syringe.<br />6. Place the syringe in the infusion pump.<br />7. For infusion you may insert the butterfly-type needle under the skin of the abdomen, arm, upper leg<br />or thigh.<br />It is important to first clean the skin very thoroughly with alcohol. Then insert the needle firmly, up<br />to the wings, into a fold of the skin formed by your free hand. The tip of the needle should move<br />freely when the needle is waggled. If it doesn&#39;t move freely, the tip of the needle may be too close to<br />the skin. Try again at a new site after cleaning it with alcohol.<br />8. Then fix the needle and tape it down.</p><p>Concomitant use of vitamin C<br />After you have had at least one month of regular treatment with Desferal, your doctor may decide that<br />you should take vitamin C also. The maximum daily dose of vitamin C for adults is 200 mg, which is<br />broken up into smaller doses that are taken over the course of the day.<br />50 mg vitamin C daily is usually sufficient for children under 10 years of age, while 100 mg will<br />generally be sufficient for older children.<br />How long to use Desferal<br />Make sure you use this medicine regularly and exactly as your doctor tells you. This will help you to get<br />the best results and reduce the risk of side effects. If you are in doubt about your treatment, ask your<br />doctor.<br />If you have questions about how long to take Desferal, talk to your doctor or pharmacist.<br />a. If you use more Desferal than you should<br />Do not take a higher dose or concentration than the one recommended by your doctor, as you may<br />experience local side effects at the injection site, as well as some other side effects such as dizziness,<br />light-headedness (signs of low blood pressure), fast or slow heart beat, gastrointestinal disorders (nausea),&nbsp;severely decreased urine output (sign of kidney disorder), nervous system disorders (e.g. agitation,<br />inability to speak, headache), breathlessness (sign of lung disorders), visual and hearing disorders.<br />If you take too much Desferal, contact your doctor or hospital for advice right away. You may need<br />medical treatment.</p><p>&nbsp;</p><p>b. If you forget to use Desferal<br />If you have missed a dose of Desferal, tell your doctor at once.<br />c. If you stop using Desferal<br />Do not stop using Desferal unless your doctor tells you to. If you stop using it, the excess iron will no<br />longer be removed from your body (see above &ldquo;How long to use Desferal&rdquo;).<br />Other uses of Desferal<br />Treatment for acute iron poisoning<br /> Desferal is used in cases of poisoning with iron preparations.<br />Treatment for chronic aluminum overload<br /> Desferal is usually given once a week, by slow infusion into a vein, either during the last 60 minutes<br />of a dialysis session, or 5 hours before a dialysis session, depending on the level of aluminium in your<br />blood.<br /> If you are receiving continuous ambulatory peritoneal dialysis (CAPD) or continuous cyclic<br />peritoneal dialysis (CCPD), you will need to take your dose of Desferal prior to the final exchange of<br />the day.<br /> The dose of Desferal is 5 mg per kilogram of body weight.<br /> Your doctor will arrange for you to be tested in order to determine how long you should be treated,<br />and whether the dose of Desferal needs to be changed.<br />Testing of iron and aluminum overload<br /> If you have to undergo testing for iron overload, you will be given an intramuscular injection of<br />Desferal and will be asked to collect your urine for 6 hours. The urine will then be checked for iron.<br /> If you have to undergo testing for aluminum overload, you will be given a slow intravenous infusion<br />of Desferal during the dialysis session. The aluminum content of blood samples taken just before this<br />dialysis session and the next one will be determined.<br />Always use Desferal exactly as your doctor or health care provider has told you. You should check with<br />your doctor, health care provider or pharmacist if you are not sure.<br />If you have any further questions on the use of this product, ask your doctor, health care provider or<br />pharmacist.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>As with all medicines, patients treated with Desferal may experience side effects, although not everybody<br />gets them.<br />Most of these side effects are mild to moderate and will generally disappear after a few days or weeks of<br />treatment. Please do not be alarmed by this list of possible side effects. Bear in mind, that you may not<br />experience any of them.<br />Side effects may occur with certain frequencies, which are defined as follows:<br />Very common side effects may affect more than 10 out of every 100 patients.<br />Common side effects may affect between 1 and 10 of every 100 patients.<br />Uncommon side effects may affect between 1 and 10 of every 1,000 patients.<br />Rare side effects may affect between 1 and 10 of every 10,000 patients.<br />Very rare side effects may affect fewer than 1 out of every 10,000 patients.<br />We use the term &ldquo;unknown frequency&rdquo; when the frequency of side effects cannot be reliably estimated.<br />Some side effects could be serious<br />Tell your doctor straight away, if you experience any of the side effects listed below:<br />Uncommon<br /> disturbances of hearing, such as ringing or noise in the ears, hearing loss<br />Rare<br /> disturbances of vision, such as blurred eyesight, abnormal colour vision, night blindness, black spots<br />in the vision, loss of vision, clouding of the lens of the eye, visual field defects or decreased sharpness<br />of vision<br /> fungal or bacterial infections leading to high fever, shortness of breath, acute diarrhea, abdominal<br />pain, general discomfort or sore throat<br /> dizziness, light-headedness (signs of low blood pressure that can occur when the drug is given too<br />rapidly)<br />Very rare<br /> breathlessness due to lung disorders<br /> unusual bleeding/bruising (a sign that levels of blood platelets are low)<br /> fever, sore throat or mouth ulcers due to infections (a sign that levels of white blood cells are low)<br /> rash, itching, hives, difficulty breathing or swallowing; feeling of tightness in the chest with wheezing<br />or coughing; dizziness; swelling, mainly of the face and throat (signs of a severe allergic reaction or<br />asthma)<br /> disturbances of the nervous system<br />Frequency unknown<br /> severely decreased output of urine (sign of a kidney problem)<br /> convulsions (mainly in patients on dialysis)<br />Other possible side effects are listed in the table below<br />Tell your doctor, if any of the side effects list below affects you severely:</p><p>Very common side effects</p><p>Injection site reactions such as pain, swelling, reddening, itching of<br />the skin, eschar, crust formation, small blisters, burning, joint or<br />muscle pain.</p><p><br />Common side effects</p><p>Nausea, headache, itchy rash, fever, reduced growth rate, bone<br />disorders.</p><p><br />Uncommon side effects</p><p>Vomiting, abdominal pain.<br />Very rare side effects Diarrhea, skin rash, sensation of numbness or tingling in fingers and<br />toes.</p><p><br />Unknown</p><p>Muscle spasms, abnormal liver or kidney function test results.<br />Hypocalcemia and aggravation of hyperparathyroidism in patients<br />treated for aluminum overload.<br />Your urine may turn reddish-brown because there is more iron in<br />your urine. This is usually nothing to worry about, but if you are<br />worried, you should talk to your doctor or nurse.</p><p><br />Tell your doctor or pharmacist, if you experience any other side effects not listed above.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p> Do not use after the expiry date shown on the pack. The expiry date refers to the last day of that<br />month.<br /> Store the Desferal vials containing the dry active substance below 30&deg;C.<br /> One vial is for single use only. The product should be used immediately after the solution has been<br />made up (reconstituted), i.e. treatment should start within 3 hours. When the solution has been<br />prepared under recognized sterile conditions, it may be stored for a maximum period of 24 hours at<br />room temperature before the start of treatment. Opaque or cloudy solutions should be discarded.<br /> Keep out of the reach and sight of children.<br /> Remember to return any unused vials to your pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance of Desferal is desferrioxamine methane sulphonate.<br />This information might differ in some countries</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Desferal powder is supplied in vials. Each vial contains 500 mg of desferrioxamine.
This information might differ in some countries.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved / revised by EMA in 05/2011
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي ديسفيرال على المادة الفعالة ديسفيريوكسامين، وهو ما يُسمَّى &quot;خالب&quot;. ويُستعمَل لإزالة الحديد الزائد أو الألومنيوم<br />الزائد من الجسم.<br />ما هي استعمالات ديسفيرال<br />إن نقل الدم المتكرر قد يكون ضرورياً في المرضى الذين يعانون من أنواع معيَّنة من الأنيميا مثل الثالسيميا. غير أن نقل الدم<br />المتكرر قد يؤدي إلى تراكم الحديد الزائد، وذلك لأن الدم يحتوي على حديد والجسم ليس لديه طريقة طبيعية للتخلص من<br />الحديد الزائد الناتج عن نقل الدم. بمرور الوقت، قد يؤدي الحديد الزائد إلى تلف أعضاء هامة مثل الكبد والقلب. يعمل<br />ديسفيرال على إزالة هذا الحديد الزائد وبالتالي يمكن استخدامه لعلاج الزيادة المزمنة في تحميل الحديد. يمكن استعمال<br />ديسفيرال لعلاج البالغين، والمراهقين، والأطفال.<br />كذلك يمكن استعماله:<br />لعلاج التسمم الحاد بالحديد، ●<br />لعلاج الزيادة المزمنة في تحميل الألومنيوم في المرضى الذين لديهم مرض كلوي شديد ويحتاجون إلى غسيل كلى ●<br />بصفة دورية. تحت ظروف معيَّنة، قد يؤدي غسيل الكلى إلى زيادة تراكم الألومنيوم.<br />لإجراء اختبار للكشف عن زيادة تحميل الحديد أو الألومنيوم. ●<br />كيف يعمل ديسفيرال<br />يعمل ديسفيرال على التقاط ونزع الحديد الزائد أو الألومنيوم الزائد، والذي يتم بعد ذلك إخراجه في البول والبراز.<br />المراقبة أثناء علاجك بواسطة ديسفيرال<br />قد تحتاج إلى إجراء اختبارات معيَّنة للدم والبول قبل وأثناء العلاج.<br />في المرضى الذين لديهم زيادة في تحميل الحديد، سيتم مراقبة مستويات الحديد )الفيريتين( في جسمك لمعرفة مدى فاعلية<br />ديسفيرال. ستُجرَى لك أيضاً اختبارات للبصر والسمع. في الأطفال سيتم قياس النمو ووزن الجسم على فترات منتظمة. سيضع<br />طبيبك هذه الاختبارات في اعتباره عند اتخاذه القرار بشأن جرعة ديسفيرال الأنسب لك.<br />سيقوم طبيبك أيضاً بتقييم وظيفة قلبك إذا كنت تأخذ فيتامين ج أثناء استعمال ديسفيرال.<br />إذا كانت لديك أي أسئلة عن الكيفية التي يعمل بها ديسفيرال أو عن سبب وصف هذا الدواء لك، برجاء أن تسأل طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>التزم بجميع تعليمات طبيبك بكل دقة. هذه التعليمات قد تكون مختلفة عن المعلومات العامة المذكورة في هذه النشرة.<br />أ. لا تستعمل ديسفيرال<br />إذا كانت لديك أرجية )حساسية مفرطة( تجاه ديسفيرال أو تجاه أي من المكونات الأخرى في ديسفيرال المذكورة في ●<br />نهاية هذه النشرة )إلا إذا أُجريت لك إزالة تحسس ناجحة مما جعل من الممكن استعمال ديسفيرال(.<br />إذا انطبق عليك ذلك، أخبر طبيبك مع الامتناع عن أخذ ديسفيرال.<br />إذا ظننت أن لديك أرجية )حساسية مفرطة( استشر طبيبك.<br />ب. يجب توخي الحذر الخاص مع ديسفيرال<br />قبل أن تستعمل ديسفيرال أخبر طبيبك إذا كان لديك:<br />أي خلل في الكلى</p><p>أخبر طبيبك فور ا ، إذا حدث لديك أي من الأعراض التالية أثناء علاجك بواسطة ديسفيرال:<br />حمى مرتفعة، التهاب في الحلق، ضيق في التنفس، ألم في البطن، إسهال حاد أو عناء عام )من أعراض العدوى الفطرية ●<br />أو البكتيرية(<br />نقص شديد في إفراز البول )من أعراض الخلل الكلوي( ●<br />خلل في البصر والسمع. ●<br />دوخة، دوار )من أعراض انخفاض ضغط الدم(، ضيق التنفس وهو قد يحدث إذا تم إعطاء الدواء بأسرع مما ينبغي عند ●<br />إعطاء ديسفيرال بالتنقيط في الوريد. انظر أيضاً تحت البند 3 &quot;إذا استعملت ديسفيرال بأكثر مما ينبغي&quot;.<br />اضطرابات في القلب، وهي من الأعراض الممكنة في المرضى الذين يستعملون ديسفيرال ويستعملون أيضاً جرعات ●<br />عالية من فيتامين ج. إذا وصف لك طبيبك إضافات من فيتامين ج، تأكد من أنك قد استعملت ديسفيرال بصفة منتظمة<br />لمدة شهر واحد على الأقل قبل أن تبدأ في أخذ فيتامين ج. أيضاً احرص على استعمال فيتامين ج فقط بالجرعات التي<br />وصفها لك طبيبك. لا تتجاوز الجرعة 200 مجم يومياً.<br />أخبر طبيبك إذا لاحظت أن:<br />طفلك الذي يتلقى ديسفيرال نموه أبطأ من الطبيعي. ●<br />برجاء ملاحظة أن البول قد يتحول إلى اللون البني المائل للاحمرار أثناء استعمال ديسفيرال، وذلك بسبب وجود المزيد من<br />الحديد في البول. لا تقلق من هذا الأمر، ولكن إذا شعرت بالقلق تحدث مع طبيبك أو الممرضة.<br />ج. استعمال أدوية أخرى<br />أخبر طبيبك أو الصيدلي إذا كنت تستعمل حالياً أو إذا كنت قد استعملت منذ فترة قصيرة أي أدوية أخرى، بالإضافة إلى<br />ديسفيرال، ويشمل ذلك الأدوية التي يتم الحصول عليها بدون تذكرة طبية، ويشمل ذلك على نحو خاص:<br />الأدوية المحتوية على بروكلوربيرازين، وهو دواء مضاد للذهان لعلاج الاضطرابات العصبية، ●<br />فيتامين ج )بجرعات فوق 200 مجم يومياً أثناء استعمال ديسفيرال(. لا تأخذ أكثر من 200 مجم فيتامين ج في اليوم ●<br />)انظر عاليه تحت بند يجب توخي الحذر الخاص(،<br />جاليوم- 67 ، وهو دواء يُعطَى قبل التصوير بالأشعة، ويُستعمَل في تشخيص أمراض معيَّنة. ●<br />قد تحتاج إلى تغيير جرعة الدواء الآخر، أو إلى وقف استعماله تماماً.<br />يرجى إخبار طبيبك، مقدم الرعاية الصحية أو الصيدلي إذا كنت تستعمل أو استعملت منذ فترة قصيرة أي أدوية أخرى بما في<br />ذلك الأدوية التي تصرف بدون وصفة طبية.<br />د. الأشخاص المسنون<br />يمكن استعمال ديسفيرال في المرضى المسنين بنفس الجرعات التي توصف لسائر الأشخاص البالغين.<br />ه. الأطفال والمراهقون<br />يمكن استعمال ديسفيرال في الأطفال أو المراهقين.<br />و. الحمل والإرضاع<br />يجب أن تخبري طبيبك إذا كنت حاملاً، أو إذا كنتِ تخططين للحمل، أو إذا كنتِ مرضعة. بصفة عامة، لا ينبغي أن تستعملي<br />ديسفيرال أثناء الحمل والإرضاع ما لم يوصي طبيبك بذلك. سوف يناقش معك طبيبك المخاطر الممكنة التي قد تترتب على<br />إعطائك ديسفيرال أثناء الحمل.<br />لا يوصَى بالإرضاع من الثدي أثناء استعمال ديسفيرال. أخبري طبيبك إذا كنتِ مرضعة.<br />استشيري طبيبكِ، مقدم الرعاية الصحية أو الصيدلي قبل استعمال أي دواء.<br />ز. قيادة السيارة وتشغيل الآلات<br />قد يؤثر ديسفيرال على إبصارك أو سمعك، أو قد يجعلك تشعر بالدوخة، أو قد يسبب اضطرابات أخرى في الوظيفة العصبية.<br />إذا حدثت لديك هذه الآثار، امتنع عن قيادة السيارة وعن تشغيل أي آلات أو ماكينات، إلى أن تصبح بحالة جيدة مرة أخرى.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>التزم بتعليمات طبيبك بكل دقة. لا تتجاوز الجرعة الموصَى بها.<br />سيقوم طبيبك بحساب الجرعة التي تحتاجها وسيخبرك ما هي الكمية التي يجب أن تأخذها من ديسفيرال. بناء على مدى<br />استجابتك للعلاج، قد يقترح طبيبك أن يعطيك جرعة أكبر أو أقل.<br />ديسفيرال مُصمَّم للاستعمال على هيئة محلول في ماء الحقن. أذب مسحوق ديسفيرال في &quot;ماء الحقن&quot; الذي أعطاه لك<br />الصيدلي. مع التركيز الموصَى به 95 مجم/ ملليلتر )للإعطاء بالحقن تحت الجلد(، يكون المحلول عديم اللون إلى مائل<br />للاصفرار. يجب أن يكون المحلول رائقاً. لا تستعمل المحاليل المعتمة أو المعكرة.</p><p>علاج الزيادة المزمنة في تحميل الحديد<br />سيضبط طبيبك الجرعة وفقاً لحالتك الخاصة. في معظم المرضى، تكون الجرعة اليومية 20 إلى 60 مجم لكل كيلوجرام من<br />وزن الجسم.<br />يمكن إعطاء ديسفيرال بالتنقيط البطيء تحت الجلد )بالحقن تحت الجلد باستخدام مضخة تنقيط(، أو بالتنقيط في الوريد، أو<br />بالحقن في العضل.<br />قد يقوم طبيبك أو الممرضة بتحضير الحقنة لك، أو قد يتم تعليمك طريقة تحضيرها لنفسك. للعلاج طويل الأجل لزيادة تحميل<br />الحديد، من الملائم على نحو خاص أن تعطي ديسفيرال لنفسك بالحقن البطيء تحت الجلد على مدى 8 إلى 12 ساعة )مثلاً<br />طول الليل(، باستخدام مضخة تنقيط محمولة خفيفة الوزن. يُستعمَل ديسفيرال عادةً بواسطة المضخة 5 إلى 7 مرات في<br />الأسبوع. يجب تحضير المضخة بعناية شديدة تحت ظروف النظافة الشديدة.<br />التزم بالتعليمات المذكورة أدناه لتحضير المحلول وللإعطاء بالتنقيط تحت الجلد:<br />-1 اسحب ماء الحقن في سرنجة.<br />-2 بعد تنظيف السدادة المطاطية لقارورة ديسفيرال بالكحول، احقن محتويات السرنجة في القارورة.<br />-3 رج القارورة جيداً لإذابة المسحوق.<br />-4 اسحب المحلول الناتج إلى داخل السرنجة.<br />-5 اربط أنبوبة الإطالة بالسرنجة، واربط أنبوبة الإطالة بالإبرة طراز الفراشة، ثم املأ الحيز الفارغ في الأنبوبة<br />بالمحلول الموجود في السرنجة.<br />-6 ضع السرنجة في مضخة التنقيط.<br />-7 لإعطاء الحقنة بالتنقيط اغرس الإبرة طراز الفراشة تحت الجلد في البطن، أو الذراع، أو أعلى الفخذ أو الفخذ.<br />من المهم أن تقوم أولاً بتنظيف الجلد بعناية شديدة بالكحول. بعد ذلك اغرس الإبرة بثبات، حتى الأجنحة، في ثنية من<br />الجلد تكوِّنها بيدك الخالية. يجب أن يكون سن الإبرة حر الحركة عند هز الإبرة. فإذا لم يكن حر الحركة، قد يكون سن<br />الإبرة أقرب من اللازم إلى سطح الجلد. في هذه الحالة، أعد محاولة الغرس في مكان آخر بعد تنظيفه بالكحول.<br />-8 بعد ذلك ثبِّت الإبرة في موضعها باستخدام شريط لاصق.<br />-9 يحمل المرضى المضخة عادة على أجسامهم بالاستعانة بحزام أو جراب يُحمل على الكتف. يرى الكثير من المرضى<br />أن الاستعمال طول الليل هو الأكثر ملاءمة.</p><p>الاستعمال بالتزامن مع فيتامين ج<br />بعد أن تكون قد استعملت ديسفيرال كعلاج منتظم لمدة شهر واحد على الأقل، قد يقرر طبيبك أن يعطيك أيضاً فيتامين ج.<br />الجرعة اليومية القصوى من فيتامين ج في البالغين هي 200 مجم، ويتم تقسيمها إلى جرعات أصغر تؤخذ على مدار اليوم.<br />يكفي عادة إعطاء 50 مجم فيتامين ج يومياً في الأطفال تحت 10 سنوات من العمر، في حين تكفي الجرعة 100 مجم بصفة<br />عامة للأطفال الأكبر سناً.<br />ما هي مدة استعمال ديسفيرال<br />احرص على استعمال هذا الدواء بانتظام وبالضبط كما وصفه لك طبيبك. هذا سيساعدك على تحقيق أفضل النتائج وتقليل<br />مخاطرة الآثار الجانبية. إذا كان لديك شك بشأن علاجك، اسأل طبيبك.<br />إذا كانت لديك أسئلة عن مدة استعمال ديسفيرال، تحدث مع طبيبك أو مع الصيدلي.<br />أ. إذا استعملت ديسفيرال بأكثر مما ينبغي<br />لا تأخذ جرعة أكبر أو تركيزاً أكبر مما وصفه لك طبيبك، حيث أن ذلك قد يؤدي إلى حدوث آثار جانبية موضعية في موضع<br />الحقن، وأيضاً بعض الآثار الجانبية الأخرى مثل الدوخة، الدوار )من أعراض انخفاض ضغط الدم(، سرعة أو بطء ضربات<br />القلب، اضطرابات هضمية )غثيان(، نقص شديد في إفراز البول )من أعراض الخلل الكلوي(، اضطرابات في الجهاز<br />العصبي )مثلاً هياج، عدم القدرة على الكلام، صداع(، ضيق في التنفس )من أعراض الخلل الرئوي(، خلل في البصر<br />والسمع.<br />إذا أخذت ديسفيرال بأكثر مما ينبغي، اتصل فوراً بطبيبك أو بالمستشفى طلباً للنصيحة، فإنك قد تحتاج إلى رعاية طبية.<br />ب. إذا نسيت أن تأخذ ديسفيرال</p><p>إذا نسيت أن تأخذ إحدى جرعات ديسفيرال، أخبر طبيبك فوراً.<br />ج. إذا توقفت عن استعمال ديسفيرال<br />لا توقف استعمال ديسفيرال ما لم يوصي طبيبك بذلك. إذا توقفت عن استعماله، فإن جسمك سيكف عن التخلص من الحديد<br />الزائد )انظر عاليه &quot;ما هي مدة استعمال ديسفيرال&quot;(.<br />الاستعمالات الأخرى لديسفيرال<br />علاج التسمم الحاد بالحديد<br />يُستعمَل ديسفيرال في حالات التسمم بمستحضرات الحديد. ●<br />علاج الزيادة المزمنة في تحميل الألومنيوم<br />يتم إعطاء ديسفيرال عادةً مرة واحدة في الأسبوع، بالتنقيط البطيء في الوريد، إما أثناء ال 60 دقيقة الأخيرة من جلسة ●<br />غسيل الكلى، أو قبل جلسة غسيل الكلى ب 5 ساعات، وفقاً لمستوى الألومنيوم في دمك.<br />أو ديلزة بريتونية دورية مستمرة (CAPD) إذا كنت تتلقى غسيل كلى بواسطة ديلزة بريتونية سَيرية مستمرة ●<br />سوف تحتاج أن تأخذ جرعتك من ديسفيرال قبل الاستبدال النهائي لليوم. ،(CCPD)<br />جرعة ديسفيرال هي 5 مجم لكل كيلوجرام من وزن الجسم. ●<br />سوف يرتب لك طبيبك إجراء اختبارات لتحديد ما هي مدة العلاج المطلوبة، وما إذا كان ينبغي تغييرجرعة ديسفيرال. ●<br />إجراء اختبار للكشف عن زيادة تحميل الحديد أو الألومنيوم<br />إذا كان من المطلوب أن يُجرَى لك اختبار للكشف عن زيادة تحميل الحديد، سيتم إعطاؤك حقنة من ديسفيرال في ●<br />العضل، وسيُطلَب منك أن تجمع البول لمدة 6 ساعات. بعد ذلك سيتم قياس الحديد في البول.<br />إذا كان من المطلوب أن يُجرَى لك اختبار للكشف عن زيادة تحميل الألومنيوم، سيتم إعطاؤك حقنة من ديسفيرال ●<br />بالتنقيط البطيء في الوريد أثناء جلسة غسيل الكلى. سيتم قياس محتوى الألومنيوم في عينات دم يتم أخذها قبل هذه<br />الجلسة من غسيل الكلى مباشرة والجلسة التالية.<br />دائماً استعمل ديسفيرال تماماً كما وصفه لك طبيبك، مقدم الرعاية الصحية أو الصيدلي. إذا لم تكن متأكداً أو لديك أي أسئلة أخرى، إسأل<br />طبيبك، مقدم الرعاية الصحية أو الصيدلي<br />&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>شأنه شأن جميع الأدوية، فإن المرضى الذين يستعملون ديسفيرال قد يتعرضون لحدوث آثار جانبية، غير أنها لا تحدث لجميع<br />الأشخاص.<br />معظم هذه الآثار الجانبية طفيفة إلى متوسطة وهي تزول غالباً بعد بضعة أيام أو بضعة أسابيع من العلاج. برجاء ألا تقلق من<br />هذه القائمة من الآثار الجانبية الممكنة، وإنما ضع في ذهنك أنك قد لا تتعرَّض لحدوث أي منها.<br />قد تحدث الآثار الجانبية بمعدلات حدوث معيَّنة ويتم تعريفها كما يلي:<br />آثار جانبية شائعة جداً قد تصيب أكثر من 10 من كل 100 مريض.<br />آثار جانبية شائعة قد تصيب بين 1 و 10 من كل 100 مريض.<br />آثار جانبية غير شائعة قد تصيب بين 1 و 10 من كل 1000 مريض.<br />آثار جانبية نادرة قد تصيب بين 1 و 10 من كل 10000 مريض.<br />آثار جانبية نادرة جداً قد تصيب أقل من 1 من كل 10000 مريض.<br />يُستعمَل مصطلح &quot;معدل حدوث غير معروف&quot; عندما لا يمكن تقدير معدل حدوث الآثار الجانبية بطريقة موثوق فيها.</p><p>&nbsp;</p><p>بعض الآثار الجانبية قد تكون خطيرة<br />أخبر طبيبك فور ا ، إذا حدث لديك أي من الآثار الجانبية المذكورة أدناه:<br />غير شائعة<br />خلل في السمع، مثلاً في شكل صفير أو طنين في الأذنين، صمم ●<br />نادرة<br />خلل في البصر، مثلاً في شكل غشاوة في الإبصار، عيوب في رؤية الألوان، عشى ليلي، بقع سوداء في مجال الإبصار، ●<br />فقدان البصر، عتامة في عدسة العين، عيوب في مجال الإبصار، أو نقص حدة الإبصار<br />عدوى فطرية أو بكتيرية تؤدي إلى حمى عالية، ضيق في التنفس، إسهال حاد، ألم بطني، عناء عام، أو التهاب في الحلق ●<br />دوخة، دوار )من أعراض انخفاض ضغط الدم والتي يمكن أن تحدث عند إعطاء الدواء بأسرع مما ينبغي( ●<br />نادرة جد ا<br />ضيق التنفس بسبب اضطرابات في الرئة ●<br />نزف غير معتاد/ كدمات )من أعراض انخفاض مستويات الصفيحات الدموية( ●<br />حمى، التهاب الحلق، أو قروح في الفم بسبب العدوى )من أعراض انخفاض مستويات خلايا الدم البيضاء( ●<br />طفح، حكة، أرتيكاريا، صعوبة في التنفس أو البلع، الشعور بضيق في الصدر مع أزيز أو سعال؛ دوخة؛ تورم، أساساً ●<br />في الوجه والحلق )من أعراض التفاعل الأرجي الشديد أو الربو(<br />اضطرابات في الجهاز العصبي ●<br />معدل حدوث غير معروف<br />نقص شديد في إفراز البول )من أعراض وجود مشكلة في الكلى( ●<br />تشنجات( أساساً في المرضى الذين يُجرَى لهم غسيل كلى)&nbsp;</p><p>الآثار الجانبية الأخرى الممكنة مذكورة في الجدول أدناه<br />أخبر طبيبك، إذا حدثت لديك إصابة شديدة بأي من الآثار الجانبية المذكورة أدناه:<br />آثار جانبية شائعة جد ا تفاعلات في موضع الحقن مثلاً ألم، تورم، احمرار، حكة في الجلد، تقشر الجلد،<br />تكوين جلبة، بثور صغيرة، حُرقة، ألم في المفاصل أو العضلات.<br />آثار جانبية شائعة غثيان، صداع، طفح مصحوب بحكة، حمى، نقص معدل النمو، خلل في العظام.<br />آثار جانبية غير شائعة قيء، ألم بطني.<br />آثار جانبية نادرة جد ا إسهال، طفح جلدي، الإحساس بخدر أو تنميل في أصابع اليدين والقدمين.<br />معدل حدوث غير معروف تشنجات عضلية، خلل في نتائج اختبارات وظائف الكبد أو الكلى.<br />نقص كالسيوم الدم وتفاقم فرط نشاط الغدة الجاردرقية في المرضى الذين يُعالَجون<br />من التحميل الزائد للألومنيوم.<br />قد يتحول البول إلى اللون البني المائل للاحمرار بسبب وجود المزيد من الحديد في<br />البول. هذا شيء لا يدعو للقلق عادةً، ولكن إذا شعرت بالقلق تحدث مع طبيبك أو<br />الممرضة.<br />أخبر طبيبك أو الصيدلي، إذا حدثت لديك أي آثار جانبية أخرى غير مذكورة عاليه.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا ينبغي استعماله بعد تاريخ انتهاء الصلاحية المذكور على العلبة الخارجية. يشير تاريخ الانتهاء إلى آخر يوم من ●<br />الشهر المذكور.<br />قوارير ديسفيرال المحتوية على المادة الجافة الفعالة يجب أن تُحفَظ في درجة حرارة أقل من 30 &deg;م. ●<br />القارورة الواحدة هي لاستخدام واحد فقط. يجب أن يُستعمَل المستحضر فوراً بعد تجهيز المحلول )إعادة تركيبه(، أي أن ●<br />العلاج يجب أن يبدأ خلال 3 ساعات. إذا كان المحلول قد تم تحضيره في ظروف التعقيم المعتمَدة، فيمكن حفظه في<br />درجة حرارة الغرفة لمدة 24 ساعة بحد أقصى قبل بدء العلاج. يجب التخلص من المحاليل المعتمة أو المعكرة.<br />يُحفظ بعيداً عن متناول ومرأى الأطفال. ●<br />تذكر أن تُعيد إلى الصيدلي أي قوارير غير مستخدَمة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة في ديسفيرال هي ديسفيريوكسامين ميثان سلفونات.<br />هذه المعلومات قد تختلف في بعض البلاد.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">يتوافر مسحوق ديسفيرال في قوارير. تحتوي كل قارورة على 500 مجم )مجم= ملليجرام(<br />هذه المعلومات قد تختلف في بعض البلاد.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p dir="RTL">www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            د‌.	تم اعتماد هذه النَّشرة من قبل منظمة الأدوية الأوروبية في: 05/2011
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Desferal Vials, 500mg.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains desferrioxamine mesilate 500mg.
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                A sterile, lyophilised powder available in vials containing 500mg of desferrioxamine mesilate.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment for chronic iron overload, e.g.<br /> transfusional haemosiderosis in patients receiving regular transfusions e.g. thalassaemia major<br /> primary and secondary haemochromatosis in patients in whom concomitant disorders (e.g. severe anaemia,<br />hypoproteinaemia, renal or cardiac failure) preclude phlebotomy.<br />Treatment for acute iron poisoning.<br />For the diagnosis of iron storage disease and certain anaemias.<br />Aluminium overload - In patients on maintenance dialysis for end stage renal failure where preventative<br />measures (e.g. reverse osmosis) have failed and with proven aluminium-related bone disease and/or<br />anaemia, dialysis encephalopathy; and for diagnosis of aluminium overload.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Desferal may be administered parenterally.<br />For parenteral administration:<br />The drug should preferably be employed in the form of a 10% solution, e.g. 500 mg: by dissolving the contents of<br />one 500mg vial in 5ml of water for injection. When administered subcutaneously the needle should not be inserted<br />too close to the dermis. The 10% Desferal solution can be diluted with routinely employed infusion solutions<br />(saline, glucose, dextrose or dextrose-saline), although these should not be used as solvent for the dry substance.<br />Dissolved Desferal can also be added to dialysis fluid and given intraperitoneally to patients on continuous<br />ambulatory peritoneal dialysis (CAPD) or continuous cyclic peritoneal dialysis (CCPD).<br />Only clear pale yellow Desferal solutions should be used. Opaque, cloudy or discoloured solutions should be<br />discarded. Heparin is pharmaceutically incompatible with Desferal solutions.<br />Treatment of acute iron poisoning<br />Adults and children:<br />Desferal may be administered parenterally. Desferal is an adjunct to standard measures generally used in treating<br />acute iron poisoning. It is important to initiate treatment as soon as possible.<br />Parenteral Desferal treatment should be considered in any of the following situations:<br /> all symptomatic patients exhibiting more than transient minor symptoms (e.g. more than one episode of<br />emesis or passage of one soft stool),<br /> patients with evidence of lethargy, significant abdominal pain, hypovolaemia, or acidosis,<br /> patients with positive abdominal radiograph results demonstrating multiple radio-opacities (the great majority<br />of these patients will go on to develop symptomatic iron poisoning),<br /> any symptomatic patient with a serum iron level greater than 300 to 350 micro g/dL regardless of the total iron<br />binding capacity (TIBC). It has also been suggested that a conservative approach without Desferal therapy or<br />challenge should be considered when serum iron levels are in the 300 to 500 micro g/dL range in asymptomatic<br />patients, as well as in those with self-limited, non-bloody emesis or diarrhoea without other symptoms.<br />The dosage and route of administration should be adapted to the severity of the poisoning.<br />Dosage:<br />The continuous intravenous administration of Desferal is the preferred route and the recommended rate for infusion<br />is 15 mg/kg per hour and should be reduced as soon as the situation permits, usually after 4 to 6 hours so that the<br />total intravenous dose does not exceed a recommended 80 mg/kg in any 24 hour period.<br />However, if the option to infuse intravenously is not available and if the intramuscular route is used the normal<br />dosage is 2 g for an adult and 1g for a child, administered as a single intramuscular dose.<br />The decision to discontinue Desferal therapy must be a clinical decision; however, the following suggested<br />criteria are believed to represent appropriate requirements for the cessation of Desferal. Chelation therapy<br />should be continued until all of the following criteria are satisfied:<br /> the patient must be free of signs and symptoms of systemic iron poisoning (e.g. no acidosis, no worsening<br />hepatoxicity),<br /> ideally, a corrected serum iron level should be normal or low (when iron level falls below 100 micro g/dL).<br />Given that laboratories cannot measure serum iron concentrations accurately in the presence of Desferal, it is<br />acceptable to discontinue Desferal when all other criteria are met if the measured serum iron concentration is not<br />elevated.<br /> Repeat abdominal radiograph test should be obtained in patients who initially demonstrated multiple radioopacities<br />to ensure they have disappeared before Desferal is discontinued because they serve as a marker for<br />continued iron absorption,<br /> If the patient initially developed vin-rose coloured urine with Desferal therapy, it seems reasonable that urine<br />colour should return to normal before halting Desferal (absence of vin-rose urine is not sufficient by itself to<br />indicate discontinuation of Desferal).<br />The effectiveness of treatment is dependent on an adequate urine output in order that the iron complex<br />(ferrioxamine) is excreted from the body. Therefore if oliguria or anuria develop, peritoneal dialysis or<br />haemodialysis may become necessary to remove ferrioxamine.<br />It should be noted that the serum iron level may rise sharply when the iron is released from the tissues.<br />Theoretically 100 mg Desferal can chelate 8.5 mg of ferric iron.<br />Chronic Iron Overload<br />The main aim of therapy in well-controlled patients is to maintain an iron balance and prevent haemosiderosis,<br />whilst in overloaded patients a negative iron balance is desirable in order to deplete the increased iron stores and to<br />prevent the toxic effects of iron.<br />Adults and children:<br />Desferal therapy should be commenced after the first 10- 20 blood transfusions, or when there is evidence from<br />clinical monitoring that chronic iron overload is present (e.g. serum ferritin &gt;1000 ng/mL. The dose and mode of<br />administration should be individually adapted according to the degree of iron overload.<br />Growth retardation may result from iron overload or excessive Desferal doses. If chelation is started before 3 years<br />of age growth must be monitored carefully and the mean daily dose should not exceed 40mg/kg. (see section 4.4<br />Special warnings and precautions for use).<br />Dose:<br />The lowest effective dose should be used. The average daily dose will probably lie between 20 and 60 mg/kg/day.<br />Patients with serum ferritin levels of &lt; 2000 ng/mL should require about 25 mg/kg/day, and those with levels<br />between 2000 and 3000 ng/mL about 35 mg/kg/day. Higher doses should only be employed if the benefit for the<br />patient outweighs the risk of unwanted effects.<br />Patients with higher serum ferritin may require up to 55 mg/kg/day. It is inadvisable to regularly exceed an average<br />daily dose of 50 mg/kg/day except when very intensive chelation is needed in patients who have completed growth.<br />If ferritin values fall below 1000 ng/mL, the risk of Desferal toxicity increases; it is important to monitor these<br />patients particularly carefully and perhaps to consider lowering the total weekly dose.<br />To assess the chelation therapy, 24 hour urinary iron excretion should initially be monitored daily. Starting with a<br />dose of 500 mg daily the dose should be raised until a plateau of iron excretion is reached. Once the appropriate<br />dose has been established, urinary iron excretion rates can be assessed at intervals of a few weeks.<br />Alternatively the mean daily dose may be adjusted based on ferritin level in order to keep the therapeutic index<br />below 0.025 (i.e. the mean daily dose (mg/kg) of Desferal divided by the serum ferritin level (micro g/L) should be<br />below 0.025). The therapeutic index is a valuable tool in protecting the patient from excess chelation, but it is not a<br />substitute for careful clinical monitoring.<br />Mode of administration:<br />Slow subcutaneous infusion using a portable, light-weight, infusion pump over a period of 8-12 hours is effective<br />and particularly convenient for ambulant patients. It may be possible to achieve a further increase in iron excretion<br />by infusing the same daily dose over a 24 hour period. Desferal should normally be used with the pump 5-7 times a<br />week. Desferal is not formulated to support subcutaneous bolus injection.<br />Since the subcutaneous infusions are more effective, intramuscular injections are given only when subcutaneous<br />infusions are not feasible<br />Elderly<br />Clinical studies of Desferal did not include sufficient numbers of subjects aged 65 years and over to determine<br />whether they respond differently compared to younger subjects. In general, dose selection for an elderly patient should<br />be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic,<br />renal, or cardiac function, and of concomitant disease or other drug therapy&rsquo; (see sections 4.4 Special warnings and<br />precautions for use and 4.8 Undesirable effects).<br />Hepatic impairment<br />No studies have been performed in patients with hepatic impairment.<br />Intravenous infusion during blood transfusion<br />The availability of an intravenous line during blood transfusions makes it possible to administer an intravenous<br />infusion, e.g. in patients who comply poorly with and/or do not tolerate subcutaneous infusions.<br />The Desferal solution should not be put directly into the blood bag but may be added to the blood line by means of<br />a &ldquo;Y&rdquo; adaptor located near to venous site of injection. The patient&rsquo;s pump should be used to administer Desferal as<br />usual. Because of the limited amount of drug that can be administered by IV infusion during blood transfusion, the<br />clinical benefit of this mode of administration is limited. Patients and nurses should be warned against accelerating<br />the infusion, as an intravenous bolus of Desferal may lead to flushing, hypotension and circulatory collapse (see<br />section 4.4 Special warnings and precautions for use).<br />Continuous intravenous infusion is recommended for patients incapable of continuing subcutaneous infusions and<br />in those who have cardiac problems secondary to iron overload. 24 hour urinary iron excretion should be measured<br />regularly where intensive chelation (i.v.) is required, and the dose adjusted accordingly. Implanted intravenous<br />systems can be used when intensive chelation is carried out.<br />Care should be taken when flushing the line to avoid a sudden infusion of residual Desferal which may be present<br />in the dead space of the line, as this may lead to flushing, hypotension and circulatory collapse (see section 4.4<br />Special warnings and precautions for use).<br />Diagnosis of iron storage disease and certain anaemias<br />The Desferal test for iron overload is based on the principle that normal subjects do not excrete more than a fraction<br />of a milligram of iron in their urine daily, and that a standard intramuscular injection of 500 mg of Desferal will not<br />increase this above 1 mg of iron (18 micro mol). In iron storage diseases, however, the increase may be well over<br />1.5 mg (27 micro mol). It should be borne in mind that the test only yields reliable results when renal function is<br />normal.<br />Desferal is administered as 500 mg intramuscular injection. Urine is then collected for a period of 6 hours and its<br />iron content determined.<br />Excretion of 1-1.5 mg (18-27 micro mol) of iron during this 6-hour period is suggestive of iron overload; values<br />greater than 1.5 mg (27 micro mol) can be regarded as pathological.<br />Treatment for aluminium overload in patients with end stage renal failure<br />Patients should receive Desferal if:<br />- they have symptoms or evidence of organ impairment due to aluminium overload<br />- they are asymptomatic but their serum aluminium levels are consistently above 60 ng/mL and associated with a<br />positive Desferal test (see below), particularly if a bone biopsy provides evidence of aluminium related bone<br />disease.<br />The iron and aluminium complexes of Desferal are dialysable. In patients with renal failure their elimination will<br />be increased by dialysis.<br />Adults and children:<br />Patients on maintenance haemodialysis or haemofiltration: 5 mg/kg once a week. Patients with postdesferrioxamine<br />test serum aluminium levels up to 300 ng/mL: Desferal should be given as a slow i.v. infusion<br />during the last 60 minutes of a dialysis session (to reduce loss of free drug in the dialysate). Patients with a postdesferrioxamine<br />test serum aluminium value above 300 ng/ml: Desferal should be administered by slow i.v.<br />infusion 5 hours prior to the dialysis session.<br />Four weeks after the completion of a three month course of Desferal treatment a Desferal infusion test should be<br />performed, followed by a second test 1 month later. Serum aluminium increases of less than 50ng/mL above<br />baseline measured in 2 successive infusion tests indicate that further Desferal treatment is not necessary.<br />Patients on CAPD or CCPD:<br />5 mg/kg once a week prior to the final exchange of the day. It is recommended that the intraperitoneal route be used<br />in these patients. However, Desferal can also be given i.m., by slow infusion i.v. or s.c.<br />Diagnosis of aluminium overload in patients with end stage renal failure<br />A Desferal infusion test is recommended in patients with serum aluminium levels &gt; 60ng/mL associated with<br />serum ferritin levels &gt;100 ng/mL.<br />Just before starting the haemodialysis session, a blood sample is taken to determine the baseline level serum<br />aluminium level.<br />During the last 60 minutes of the haemodialysis session a 5mg/kg dose is given as a slow intravenous infusion.<br />At the start of the next haemodialysis session (i.e. 44 hours after the aforementioned Desferal infusion) the second<br />blood sample is taken to determine the serum aluminium level once more.<br />An increase in serum aluminium above baseline of more than 150 ng/mL is suggestive of aluminium overload. It<br />should be noted that a negative test does not completely exclude the possibility of aluminium overload.<br />Theoretically 100 mg Desferal can bind 4.1 mg Al+++.<br />Use in the elderly<br />No special dosage regime is necessary but concurrent renal insufficiency should be taken into account.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to desferrioxamine mesilate unless the patients can be desensitised.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Renal impairment<br />Desferal should be used with caution in patients with renal impairment since the metal complexes are excreted via<br />the kidneys. In these patients, dialysis will increase the elimination of chelated iron and aluminium. Isolated cases<br />of acute renal failure have been reported (see also section 4.8 Undesirable effects). Monitoring patients for<br />changes in renal function (e.g. increased serum creatinine) should be considered.<br />Neurological impairment<br />Used alone Desferal may exacerbate neurological impairment in patients with aluminium-related encephalopathy.<br />This deterioration (manifest as seizures) is probably related to an acute increase in brain aluminium secondary to<br />elevated circulating levels. Pretreatment with clonazepam has been shown to afford protection against such<br />impairment. Also, treatment of aluminium overload may result in decreased serum calcium and aggravation of<br />hyperparathyroidism.<br />Rapid intravenous infusion<br />Treatment with Desferal by the intravenous route should only be administered in the form of slow infusions. Rapid<br />intravenous infusion may lead to hypotension and shock (e.g. flushing, tachycardia, circulatory collapse and<br />urticaria).<br />Instructions for use and handling<br />Desferal should not be administered s.c. in concentrations and/or doses higher than those recommended as local<br />irritation at the site of administration may occur more frequently.<br />Infections<br />Patients suffering from iron overload are particularly susceptible to infection. There have been reports of Desferal<br />promoting some infections such as Yersinia enterocolitica and Y. pseudotuberculosis. If patients develop fever<br />with pharyngitis, diffuse abdominal pain or enteritis/enterocolitis, Desferal therapy should be stopped, and<br />appropriate treatment with antibiotics should be instituted. Desferal therapy may be resumed once the infection has<br />cleared.<br />In patients, receiving Desferal for aluminium and/or iron overload there have been rare reports of mucormycosis (a<br />severe fungal infection), some with fatal outcome. If any characteristic signs or symptoms occur Desferal<br />treatment should be discontinued, mycological tests carried out and appropriate treatment immediately instituted.<br />Mucormycosis has been reported to occur in dialysis patients not receiving Desferal, thus no causal link with the<br />use of the drug has been established.<br />Visual and hearing impairment<br />Disturbances of vision and hearing have been reported during prolonged Desferal therapy. In particular, this has<br />occurred in patients on higher than recommended therapy or in patients with low serum ferritin levels. Patients with<br />renal failure who are receiving maintenance dialysis and have low ferritin levels may be particularly prone to<br />adverse reactions, visual symptoms having been reported after single doses of Desferal. Therefore,<br />ophthalmological and audiological tests should be carried out both prior to the institution of therapy with Desferal<br />and at 3-monthly intervals during treatment particularly if ferritin levels are low. By keeping the ratio of the mean<br />daily dose (mg/kg of Desferal) divided by the serum ferritin (micro g/L) below 0.025 the risk of audiometric<br />abnormalities may be reduced in thalassaemia patients. A detailed ophthalmological assessment is recommended<br />(visual field measurements, fundoscopy, and colour vision testing using pseudoisochromatic plates and the<br />Farnsworth D-15 colour test, slit lamp investigation, visual evoked potential studies).<br />If disturbances of vision or hearing do occur, treatment with Desferal should be stopped. Such disturbances are<br />usually reversible. If Desferal therapy is re-instituted later at a lower dosage, close monitoring of<br />ophthalmological/auditory function should be carried out with due regard to the risk-benefit ratio.<br />Paediatrics: growth retardation<br />The use of inappropriately high doses of Desferal in patients with low ferritin levels or young children (&lt;3 years at<br />commencement of treatment) has also been associated with growth retardation; dose reduction has been found to<br />restore the growth rate to pretreatment levels in some cases. Three monthly checks on body weight and height are<br />recommended in children.<br />Growth retardation if associated with excessive doses of Desferal must be distinguished from growth retardation<br />from iron overload. Growth retardation from Desferal use is rare if the dose is kept below 40 mg/kg; if growth<br />retardation has been associated with doses above this value, then reduction of the dose may result in return in<br />growth velocity, however, predicted adult height is not attained.<br />Acute respiratory distress syndrome<br />Acute respiratory distress syndrome has been described following treatment with excessively high i.v. doses of<br />Desferal in patients with acute iron intoxication, and also in thalassaemic patients (see section 4.8 Undesirable<br />effects). The recommended daily doses should therefore not be exceeded.<br />It should be noted that desferrioxamine will affect aluminium levels and may necessitate some dosage adjustment<br />of erythropoietin if co-prescribed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oral administration of vitamin C (up to a maximum of 200 mg daily, given in divided doses) may serve to enhance<br />excretion of the iron complex in response to Desferal; larger doses of vitamin C fail to produce an additional effect.<br />Monitoring of cardiac function is indicated during such combined therapy. Vitamin C should be given only if the<br />patient is receiving Desferal regularly and should not be administered within the first month of Desferal therapy. In<br />patients with severe chronic iron-storage disease undergoing combined treatment with Desferal and high doses of<br />vitamin C (more than 500 mg daily) impairment of cardiac function has been encountered; this proved reversible<br />when the vitamin C was withdrawn. Vitamin C supplements should not, therefore, be given to patients with cardiac<br />failure.<br />Desferal should not be used in combination with prochlorperazine (a phenothiazine derivative) since prolonged<br />unconsciousness may result.<br />Gallium67 imaging results may be distorted because of the rapid urinary excretion of Desferal-bound radiolabel.<br />Discontinuation of Desferal 48 hours prior to scintigraphy is advised.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of child-bearing potential<br />In women of child-bearing potential, each case the benefits for the mother must be weighed against the risks for the<br />child.<br />Pregnancy<br />There is a limited amount of data on the use of desferrioxamine in pregnant patients. Studies in animals (rabbits)<br />have shown reproductive toxicity/teratogenicity (see section 5.3 Preclinical safety data). The risk to the<br />foetus/mother is unknown.<br />Desferal should be used during pregnancy only if the expected benefits to the mother outweigh the potential risk to the<br />foetus.<br />Breastfeeding<br />It is not known whether Desferal is excreted into the breast milk. Because many drugs are excreted in human milk,<br />and because of the potential for serious adverse drug reactions in breast-fed newborns/infants, a decision should be<br />made whether to abstain from breast-feeding or to abstain from using the medicinal product, taking into account the<br />importance of the medicinal product to the mother.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients experiencing CNS effects such as dizziness or impaired vision or hearing should be warned against driving<br />or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions (Table 1) are ranked under heading of frequency, the most frequent<br />first, using the following convention: very common ( 1/10); common ( 1/100 to &lt; 1/10);<br />uncommon ( 1/1,000 to &le; 1/100); rare ( 1/10,000 to &le; 1/1,000); very rare (&le; 1/10,000) including isolated reports;<br />not known (cannot be estimated from the available data).<br />Some signs and symptoms reported as adverse effects may also be manifestations of the underlying disease (iron<br />and/or aluminium overload).<br />Table 1<br />Infections and infestations<br />Rare: Mucormycosis infections have been reported (see 4.4 Special warnings and<br />precautions for use).<br />Very rare: Gastroenteritis yersinia infections have been reported (see 4.4 Special warnings<br />and precautions for use).<br />Blood and lymphatic system disorders<br />Very rare: blood disorders including thrombocytopenia<br />Unknown: leukopenia<br />Immune system disorders<br />Very rare: anaphylactic shock, anaphylactic reactions, angioneurotic oedema.<br />Nervous system disorders<br />Very rare: neurological disturbances, including dizziness, precipitation or exacerbation of<br />aluminium-related dialysis encephalopathy, neuropathy peripheral, paraesthesia (see 4.4<br />Special warnings and precautions for use).<br />Unknown: convulsion.<br />Eye disorders<br />Rare: loss of vision, scotoma, retinal degeneration, optic neuritis, cataracts (visual acuity<br />decreased), blurred vision, night blindness, visual field defects, chromatopsia (impairment of<br />colour vision), corneal opacities, (see 4.4. Special warnings and precautions for use). Eye<br />disorders are rare, except if high doses are given.<br />Ear and labyrinth disorders<br />Uncommon: deafness neurosensory, tinnitus (see 4.4. Special warnings and precautions for<br />use). Keeping within dose guidelines helps minimise risk of hearing side effects.<br />Vascular disorders<br />Rare: hypotension, tachycardia and shock if precautions for administration are not adhered to<br />(see 4.2 Posology and method of administration and 4.4 Special warnings and<br />precautions for use).<br />Respiratory, thoracic and mediastinal disorders<br />Very rare: acute respiratory distress lung infiltration (see 4.4 Special warnings and<br />precautions for use).<br />Gastrointestinal disorders<br />Very rare: diarrhoea.<br />Skin and subcutaneous tissue disorders<br />Very rare: rash generalised.<br />Musculoskeletal and connective tissue disorders<br />Common: growth retardation and bone disorder (e.g. metaphyseal dysplasia) are common in<br />chelated patients given doses of 60 mg/kg, especially those who begin iron chelation in the<br />first three years of life. If doses are kept to 40 mg/kg or below, the risk is considerably<br />reduced (see 4.4 Special warnings and precautions for use).<br />Unknown: muscle spasms.<br />Renal and urinary disorders<br />Unknown: acute renal failure, renal tubular disorder, blood creatinine increased (see 4.4<br />Special warnings and precautions for use and section 4.9 Overdose).<br />Special remarks<br />At the injection site pain, swelling, infiltration, erythema, pruritus and eschar/crust are very common; vesicles, local<br />oedema and burning are uncommon reactions. The local manifestations may be accompanied by systemic reactions<br />like arthralgia/myalgia (very common), headache (common), urticaria (common), nausea (common), pyrexia<br />(common), vomiting (uncommon), or abdominal pain (uncommon) or asthma (uncommon).<br />Excretion of the iron complex may cause reddish-brown discoloration of the urine.<br />Convulsion has been mainly reported in dialysed patients with aluminium overload.<br />Patients treated for chronic aluminum overload<br />Desferal chelation therapy aluminum overload may result in hypocalcemia and aggravation of hyperparathyroidism<br />(see section 4.4 Special warnings and precautions for use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Desferal is usually administered parenterally and acute poisoning is unlikely to occur.<br />Signs and symptoms: tachycardia, hypotension and gastro-intestinal symptoms have occasionally occurred in<br />patients who received an overdose of Desferal. Accidental administration of Desferal by the i.v. route may be<br />associated with acute but transient loss of vision, aphasia, agitation, headache, nausea, bradycardia, hypotension<br />and acute renal failure (see section 4.8 Undesirable effects).<br />Acute respiratory distress syndrome has been described following treatment with excessively high i.v. doses of<br />Desferal in patients with acute iron intoxication, and also in thalassemic patients (see also section 4.4 Special<br />warnings and precautions for use).<br />Treatment: there is no specific antidote to Desferal but signs and symptoms may be eliminated by reducing the<br />dosage and Desferal is dialysable. Appropriate supportive therapy should be instituted.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Chelating agent (ATC code: V03AC01)<br />Desferal is a chelating agent for trivalent iron and aluminium ions; the resulting chelates (ferrioxamine and<br />aluminoxamine) are stable and non-toxic. Neither chelate undergoes intestinal absorption, and any formed<br />systemically as a result of parenteral administration is rapidly excreted via the kidneys without deleterious effects.<br />Desferal takes up iron either free or bound to ferritin and haemosiderin. Similarly it mobilises and chelates tissue<br />bound aluminium. It does not remove iron from haemin containing substances including haemoglobin and<br />transferrin. Since both ferrioxamine and aluminoxamine are completely excreted, Desferal promotes the excretion<br />of iron and aluminium in urine and faeces, thus reducing pathological iron or aluminium deposits in the organs and<br />tissues.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Desferrioxamine is rapidly absorbed after intramuscular bolus injection or slow subcutaneous infusion, but is only<br />poorly absorbed from the gastrointestinal tract in the presence of intact mucosa.<br />During peritoneal dialysis desferrioxamine is absorbed if administered in the dialysis fluid.<br />Distribution<br />In healthy volunteers peak plasma concentrations of desferrioxamine (15.5 micro mol/L (87 micro g/mL)) were<br />measured 30 minutes after an intramuscular injection of 10 mg/kg desferrioxamine. One hour after injection the<br />peak concentration of ferrioxamine was 3.7 micro mol/L (2.3 micro g/mL). Less than 10% of desferrioxamine is<br />bound to serum proteins in vitro.<br />Biotransformation<br />Four metabolites of desferrioxamine were isolated from the urine of patients with iron overload. The following<br />biotransformation reactions were found to occur with desferrioxamine: transamination and oxidation yielding an<br />acid metabolite, beta-oxidation also yielding an acid metabolite, decarboxylation and N-hydroxylation yielding<br />neutral metabolites.<br />Elimination<br />Both desferrioxamine and ferrioxamine a biphasic elimination after intramuscular injection in healthy volunteers;<br />for desferrioxamine the apparent distribution half-life is 1 hour, and for ferrioxamine 2.4 hours. The apparent<br />terminal half-life is 6 hours for both. Within six hours of injection, 22% of the dose appears in the urine as<br />desferrioxamine and 1% as ferrioxamine.<br />Characteristics in patients<br />In patients with haemochromatosis peak plasma levels of 7.0 micro mol/L (3.9 micro g/mL) were measured for<br />desferrioxamine, and 15.7 micro mol/L (9.6 micro g/mL) for ferrioxamine, 1 hour after an intramuscular injection<br />of 10 mg/kg desferrioxamine. These patients eliminated desferrioxamine and ferrioxamine with half-lives of 5.6<br />and 4.6 hours respectively. Six hours after the injection 17% of the dose was excreted in the urine as<br />desferrioxamine and 12% as ferrioxamine.<br />In patients dialysed for renal failure who received 40 mg/kg desferrioxamine infused i.v. within 1 hour, the plasma<br />concentration at the end of the infusion was 152 micro mol/L (85.2 micro g/mL) when the infusion was given<br />between dialysis sessions. Plasma concentrations of desferrioxamine were between 13% and 27% lower when the<br />infusion was administered during dialysis. Concentrations of ferrioxamine were in all cases approximately 7.0<br />micro mol/L (4.3 micro g/mL) with concomitant aluminoxamine levels of 2-3 micro mol/litre (1.2-1.8 micro g/mL).<br />After the infusion was discontinued, the plasma concentrations of desferrioxamine decreased rapidly with a halflife<br />of 20 minutes. A smaller fraction of the dose was eliminated with a longer half-life of 14 hours. Plasma<br />concentrations of aluminoxamine continued to increase for up to 48 hours post-infusion and reached values of<br />approximately 7 micro mol/L (4 micro g/mL). Following dialysis the plasma concentration of aluminoxamine fell<br />to 2.2 micro mol/L (1.3 micro g/mL), indicating that the aluminoxamine complex is dialysable.<br />In patients with thalassaemia continuous intravenous infusion of 50mg/kg/24h of desferrioxamine resulted in<br />plasma steady state levels of desferrioxamine of 7.4 micro mol/L. Elimination of desferrioxamine from plasma<br />was biphasic with a mean distribution half-life of 0.28 hours and an apparent terminal half-life of 3.0 hours. The<br />total plasma clearance was 0.5 L/h/kg and the volume of distribution at steady state was estimated at 1.35 L/kg.<br />Exposure to the main iron binding metabolite was around 54% of that of desferrioxamine in terms of AUC. The<br />apparent monoexponential elimination half-life of the metabolite was 1.3 hours.<br />Clinical studies<br />Desferrioxamine was used as a comparator in a randomized, one-year clinical trial investigating the use of another<br />iron chelator (deferasirox) in patients with beta-thalassemia and transfusional hemosiderosis. A total of 290 patients<br />were treated with subcutaneous desferrioxamine at starting doses of 20 to 60 mg/kg for 5 days per week. The study<br />showed a dose-dependent effect of desferrioxamine on serum ferritin levels, liver iron concentration and iron<br />excretion rate.<br />Desferrioxamine was also used as a comparator in a second open-label, randomized, one-year trial investigating the<br />use of deferasirox in patients with sickle cell disease and transfusional hemosiderosis. A total of 63 patients were<br />treated with subcutaneous desferrioxamine at starting doses of 20 to 60 mg/kg at least 5 days per week. At the end<br />of the study, the mean change in liver iron concentration (LIC) was -0.7 mg Fe/g dry weight.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no preclinical data of relevance to the prescriber which are additional to that already included in other<br />sections of the Summary of Product Characteristics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None present.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Heparin injectable solution.<br />Physiological saline (0.9%) should not be used as a solvent for the dry substance, but after reconstitution<br />of the Desferal solution with water for injection, it can be employed for further dilution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vial: Store below 30C.<br />Reconstituted solution : Single use only.<br />From a microbiological point of view, the product should be used immediately after reconstitution (commencement<br />of treatment within 3 hours). When the reconstitution is carried out under validated aseptic conditions the<br />reconstituted solution may be stored for a maximum of 24 hours at room temperature (25C or below) before<br />administration. If not used immediately, in-use storage times and conditions prior to administration are the<br />responsibility of the user. Unused solution should be discarded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each vial contains a white to practically white lyophilisate supplied in a clear glass vial in a pack size of 10 (500<br />mg)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None stated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2011
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>